Optimal Bayesian-feasible dose escalation for cancer phase I trials

S. Zacks, A. Rogatko and J. Babb

Statistics & Probability Letters, 1998, vol. 38, issue 3, 215-220

Abstract: We present an adaptive dose escalation scheme for cancer phase I clinical trials which is based on a parametric quantal response model. The dose escalation is Bayesian-feasible, Bayesian-optimal and consistent. It is designed to approach the maximum tolerated dose as fast as possible subject to the constraint that the predicted probability of assigning doses higher than the maximum tolerated dose is equal to a specified value.

Keywords: Dose; escalation; scheme; Cancer; phase; I; clinical; trials; Bayesian; adaptive; procedure; Constrained; optimization; Bayesian; feasible; scheme; Consistent; escalation; scheme (search for similar items in EconPapers)
Date: 1998
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (4)

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0167-7152(98)00016-9
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:stapro:v:38:y:1998:i:3:p:215-220

Ordering information: This journal article can be ordered from
http://www.elsevier.com/wps/find/supportfaq.cws_home/regional
https://shop.elsevie ... _01_ooc_1&version=01

Access Statistics for this article

Statistics & Probability Letters is currently edited by Somnath Datta and Hira L. Koul

More articles in Statistics & Probability Letters from Elsevier
Bibliographic data for series maintained by Catherine Liu ().